{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T12:32:13Z","timestamp":1787142733721,"version":"build-2736575974"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41571-026-01185-4","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T17:08:02Z","timestamp":1784048882000},"page":"732-732","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ciltacabtagene autoleucel heralds the arrival of fixed-duration therapies in myeloma"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6464-783X","authenticated-orcid":false,"given":"Ghulam Rehman","family":"Mohyuddin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5977-907X","authenticated-orcid":false,"given":"Edward R. Scheffer","family":"Cliff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajshekhar","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"1185_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-026-01159-6","author":"GR Mohyuddin","year":"2026","unstructured":"Mohyuddin, G. R., Cliff, E. R. S. & Chakraborty, R. Does ciltacabtagene autoleucel have a future in multiple myeloma? Nat. Rev. Clin. Oncol. https:\/\/doi.org\/10.1038\/s41571-026-01159-6 (2026).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1185_CR2","doi-asserted-by":"publisher","unstructured":"Merz, M. & Gagelmann, N. The future of ciltacabtagene autoleucel in multiple myeloma has just begun. https:\/\/doi.org\/10.1038\/s41571-026-01184-5 (2026).","DOI":"10.1038\/s41571-026-01184-5"},{"key":"1185_CR3","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1200\/JCO-25-00760","volume":"43","author":"S Jagannath","year":"2025","unstructured":"Jagannath, S. et al. Long-term (\u22655-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma. J. Clin. Oncol. 43, 2766\u20132771 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1185_CR4","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1200\/OP-25-00322","volume":"22","author":"GR Mohyuddin","year":"2026","unstructured":"Mohyuddin, G. R. et al. Patient preferences on clinical decision making in multiple myeloma. JCO Oncol. Pract. 22, 877\u2013882 (2026).","journal-title":"JCO Oncol. Pract."},{"key":"1185_CR5","first-page":"Doc10","volume":"5","author":"AC M\u00fchlbacher","year":"2008","unstructured":"M\u00fchlbacher, A. C., Lincke, H.-J. & N\u00fcbling, M. Evaluating patients\u2019 preferences for multiple myeloma therapy, a discrete-choice-experiment. Psychosoc. Med. 5, Doc10 (2008).","journal-title":"Psychosoc. Med."},{"key":"1185_CR6","doi-asserted-by":"publisher","first-page":"5898","DOI":"10.1182\/bloodadvances.2023010539","volume":"7","author":"G Reynolds","year":"2023","unstructured":"Reynolds, G. et al. Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis. Blood Adv. 7, 5898\u20135903 (2023).","journal-title":"Blood Adv."},{"key":"1185_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70396","volume":"10","author":"G Vega","year":"2026","unstructured":"Vega, G. et al. Sustained disease remission after a limited duration of bispecific antibody therapy in patients with multiple myeloma. Hemasphere 10, e70396 (2026).","journal-title":"Hemasphere"},{"key":"1185_CR8","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/s41591-025-04121-8","volume":"32","author":"M Ho","year":"2026","unstructured":"Ho, M. et al. CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy. Nat. Med. 32, 702\u2013716 (2026).","journal-title":"Nat. Med."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01185-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01185-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01185-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T12:01:44Z","timestamp":1787140904000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01185-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":8,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1185"],"URL":"https:\/\/doi.org\/10.1038\/s41571-026-01185-4","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"assertion":[{"value":"14 July 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.R.M. has received funding from Janssen and Sanofi. R.C. reports consulting for Janssen, Sanofi and Adaptive; and has acted as a consultant and\/or adviser of Adaptive, Janssen and Sanofi. E.R.S.C. has received research funding from Arnold Ventures.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}